161 related articles for article (PubMed ID: 38553623)
1. Ataxia telangiectasia and Rad3-related (ATR) inhibition by VE-822 potently reversed 5-flourouracil resistance in colorectal cancer cells through targeting DNA damage response.
Mihanfar A; Asghari F; Majidinia M
Mol Biol Rep; 2024 Mar; 51(1):474. PubMed ID: 38553623
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of Ataxia-Telangiectasia Mutated and RAD3-Related (
Combès E; Andrade AF; Tosi D; Michaud HA; Coquel F; Garambois V; Desigaud D; Jarlier M; Coquelle A; Pasero P; Bonnefoy N; Moreaux J; Martineau P; Del Rio M; Beijersbergen RL; Vezzio-Vie N; Gongora C
Cancer Res; 2019 Jun; 79(11):2933-2946. PubMed ID: 30987998
[TBL] [Abstract][Full Text] [Related]
3. ATF2 loss promotes 5-FU resistance in colon cancer cells via activation of the ATR-Chk1 damage response pathway.
Yang H; Huebner K; Hampel C; Erlenbach-Wuensch K; Selvamani SB; Shukla V; Geppert CI; Hartmann A; Mahadevan V; Schneider-Stock R
BMC Cancer; 2023 May; 23(1):480. PubMed ID: 37237279
[TBL] [Abstract][Full Text] [Related]
4. ZEB1 inhibition sensitizes cells to the ATR inhibitor VE-821 by abrogating epithelial-mesenchymal transition and enhancing DNA damage.
Song N; Jing W; Li C; Bai M; Cheng Y; Li H; Hou K; Li Y; Wang K; Li Z; Liu Y; Qu X; Che X
Cell Cycle; 2018; 17(5):595-604. PubMed ID: 29157079
[TBL] [Abstract][Full Text] [Related]
5. Small-molecule inhibitors of Ataxia Telangiectasia and Rad3 related kinase (ATR) sensitize lymphoma cells to UVA radiation.
Biskup E; Naym DG; Gniadecki R
J Dermatol Sci; 2016 Dec; 84(3):239-247. PubMed ID: 27743911
[TBL] [Abstract][Full Text] [Related]
6. The antiproliferative effects of ataxia-telangiectasia mutated and ATM- and Rad3-related inhibitions and their enhancements with the cytotoxicity of DNA damaging agents in cholangiocarcinoma cells.
Moolmuang B; Ruchirawat M
J Pharm Pharmacol; 2021 Mar; 73(1):40-51. PubMed ID: 33791808
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of ATR-dependent feedback activation of Chk1 sensitises cancer cells to Chk1 inhibitor monotherapy.
Massey AJ
Cancer Lett; 2016 Dec; 383(1):41-52. PubMed ID: 27693461
[TBL] [Abstract][Full Text] [Related]
8. The identification of the ATR inhibitor VE-822 as a therapeutic strategy for enhancing cisplatin chemosensitivity in esophageal squamous cell carcinoma.
Shi Q; Shen LY; Dong B; Fu H; Kang XZ; Yang YB; Dai L; Yan WP; Xiong HC; Liang Z; Chen KN
Cancer Lett; 2018 Sep; 432():56-68. PubMed ID: 29890208
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of Wee1 sensitizes AML cells to ATR inhibitor VE-822-induced DNA damage and apoptosis.
Qi W; Xu X; Wang M; Li X; Wang C; Sun L; Zhao D; Sun L
Biochem Pharmacol; 2019 Jun; 164():273-282. PubMed ID: 31014753
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of the ATR kinase enhances 5-FU sensitivity independently of nonhomologous end-joining and homologous recombination repair pathways.
Ito SS; Nakagawa Y; Matsubayashi M; Sakaguchi YM; Kobashigawa S; Matsui TK; Nanaura H; Nakanishi M; Kitayoshi F; Kikuchi S; Kajihara A; Tamaki S; Sugie K; Kashino G; Takahashi A; Hasegawa M; Mori E; Kirita T
J Biol Chem; 2020 Sep; 295(37):12946-12961. PubMed ID: 32675286
[TBL] [Abstract][Full Text] [Related]
11. Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation.
Fokas E; Prevo R; Pollard JR; Reaper PM; Charlton PA; Cornelissen B; Vallis KA; Hammond EM; Olcina MM; Gillies McKenna W; Muschel RJ; Brunner TB
Cell Death Dis; 2012 Dec; 3(12):e441. PubMed ID: 23222511
[TBL] [Abstract][Full Text] [Related]
12. 53BP1 loss induces chemoresistance of colorectal cancer cells to 5-fluorouracil by inhibiting the ATM-CHK2-P53 pathway.
Yao J; Huang A; Zheng X; Liu T; Lin Z; Zhang S; Yang Q; Zhang T; Ma H
J Cancer Res Clin Oncol; 2017 Mar; 143(3):419-431. PubMed ID: 27838786
[TBL] [Abstract][Full Text] [Related]
13. [Suppression of ATR reverses the cisplatin resistance in ovarian cancer SKOV3 cells].
Yang Z; Sun C; Liu Y; Gong C; Chen G; Weng D
Zhonghua Zhong Liu Za Zhi; 2014 Nov; 36(11):805-10. PubMed ID: 25620475
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of the ATR-CHK1 Pathway in Ewing Sarcoma Cells Causes DNA Damage and Apoptosis via the CDK2-Mediated Degradation of RRM2.
Koppenhafer SL; Goss KL; Terry WW; Gordon DJ
Mol Cancer Res; 2020 Jan; 18(1):91-104. PubMed ID: 31649026
[TBL] [Abstract][Full Text] [Related]
15. Targeting radiation-resistant hypoxic tumour cells through ATR inhibition.
Pires IM; Olcina MM; Anbalagan S; Pollard JR; Reaper PM; Charlton PA; McKenna WG; Hammond EM
Br J Cancer; 2012 Jul; 107(2):291-9. PubMed ID: 22713662
[TBL] [Abstract][Full Text] [Related]
16. Cancer-Specific Synthetic Lethality between ATR and CHK1 Kinase Activities.
Sanjiv K; Hagenkort A; Calderón-Montaño JM; Koolmeister T; Reaper PM; Mortusewicz O; Jacques SA; Kuiper RV; Schultz N; Scobie M; Charlton PA; Pollard JR; Berglund UW; Altun M; Helleday T
Cell Rep; 2016 Jan; 14(2):298-309. PubMed ID: 26748709
[TBL] [Abstract][Full Text] [Related]
17. Targeting a non-oncogene addiction to the ATR/CHK1 axis for the treatment of small cell lung cancer.
Doerr F; George J; Schmitt A; Beleggia F; Rehkämper T; Hermann S; Walter V; Weber JP; Thomas RK; Wittersheim M; Büttner R; Persigehl T; Reinhardt HC
Sci Rep; 2017 Nov; 7(1):15511. PubMed ID: 29138515
[TBL] [Abstract][Full Text] [Related]
18. ATR mediates cisplatin resistance in 3D-cultured breast cancer cells via translesion DNA synthesis modulation.
Gomes LR; Rocha CRR; Martins DJ; Fiore APZP; Kinker GS; Bruni-Cardoso A; Menck CFM
Cell Death Dis; 2019 Jun; 10(6):459. PubMed ID: 31189884
[TBL] [Abstract][Full Text] [Related]
19. Hsp90 inhibitor-mediated disruption of chaperone association of ATR with hsp90 sensitizes cancer cells to DNA damage.
Ha K; Fiskus W; Rao R; Balusu R; Venkannagari S; Nalabothula NR; Bhalla KN
Mol Cancer Ther; 2011 Jul; 10(7):1194-206. PubMed ID: 21566061
[TBL] [Abstract][Full Text] [Related]
20. Abrogation of ATR function preferentially augments cisplatin-induced cytotoxicity in PTEN-deficient breast cancer cells.
Zhao JL; Yang J; Li K; Chen Y; Tang M; Zhu HL; Nie CL; Yuan Z; Zhao XY
Chem Biol Interact; 2023 Nov; 385():110740. PubMed ID: 37802411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]